Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyDominik R Berthold, Gregory R Pond, Freidele Soban, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 studyDominik R Berthold, Gregory R Pond, Martin Roessner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2012
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, et al.
European Urology|December 31, 2010
Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experienceJeremy F Sturgeon, Malcolm J Moore, David M Kakiashvili, et al.
The Lancet. Oncology|October 13, 2022
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trialAlexandros Papachristofilou, Jens Bedke, Stefanie Hayoz, et al.
Clinical Genitourinary Cancer|November 22, 2017
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient PopulationAndrea Necchi, Gregory R Pond, Sumanta K Pal, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2025
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trialGuilhem Roubaud, Marie Kostine, Raymond S McDermott, et al.
The Journal of Urology|July 18, 2018
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial CarcinomaGuru P Sonpavde, Luigi Mariani, Salvatore Lo Vullo, et al.
European Urology Oncology|August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract CancersNieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.
European Urology Focus|July 30, 2017
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre StudyAndrea Necchi, Gregory R Pond, Marc C Smaldone, et al.
Pageof 3